Risk of serious bloodstream infections is low in pediatric hematopoietic stem cell transplant (HSCT) recipients with fevers due to antithymocyte globulins and alemtuzumab

接受抗胸腺细胞球蛋白和阿仑单抗治疗的儿童造血干细胞移植（HSCT）受者出现发热时，发生严重血流感染的风险较低。